Novartis announced Q3 revenue of USD 13.9 billion representing 7% year-on-year (YoY) growth, with 9-month cumulative sales reaching USD 41.2 billion. The company's cardiovascular-renal-metabolic, immunology, neuroscience and oncology divisions demonstrated strong performance with 19%, 10%, 26% and 20% growth respectively through the first three quarters. Blockbuster products (exceeding USD 1 billion sales) included Kisqali (ribociclib), Kesimpta (ofatumumab), Pluvicto (lutetium Lu-177 vipivotide tetraxetan), Leqvio (inclisiran) and Scemblix (asciminib), all showing over 30% expansion due to demand in breast cancer, multiple sclerosis (MS), prostate cancer and hypercholesterolaemia.

STAMP inhibitor Scemblix achieved 84% growth to USD 894 million in the first 9 months, positioning itself for blockbuster status and showing potential in treatment-resistant chronic myeloid leukemia (CML). Cardiovascular franchise leader Entresto (sacubitril + valsartan) generated USD 6.5 billion despite US generic competition, while PCSK9-targeting Leqvio grew 61% to USD 863 million with label expansion initiatives. Radioligand platform Pluvicto and Lutathera (lutetium Lu-177 dotatate) reached USD 2.0 billion revenue with a new metastatic hormone-sensitive prostate cancer (mHSPC) application submission planned by year-end. Novartis reaffirmed full-year guidance, expecting high single-digit sales growth across its therapeutic portfolios.

PharmCube's NextBiopharm® database shows that the company focuses on oncology and rare diseases. Click here to request a free trial for NextBiopharm®.